Press Release: Rilzabrutinib LUNA 3 phase 3 study met ...

Rilzabrutinib's LUNA 3 phase 3 study met its primary endpoint, showing significant durable platelet response in ITP patients. Regulatory submissions in the US and EU are expected by year-end. Rilzabrutinib, part of Sanofi's immunology pipeline, is also being studied for other immune-mediated diseases.